U.S. License Holder:
Amgen
Date of License:
September-27-2006
Last Update:
Jan-23-2025
FDA-Approved Indications
VECTIBIX (panitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of:
Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) Metastatic Colorectal Cancer (mCRC):
In combination with FOLFOX for first-line treatment;
As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy;
KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC): In combination with sotorasib, for the treatment of adult patients with KRAS G12C-mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.